The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Original Article: CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2 phase 3a trial) https: t.co qeoRH9mdiG Editorial: Expanding the Treat to Target Toolbox for Obesity and Diabetes Care https: t.co Cagrilintide and semaglutide act individually on both EI and EE a, Download Scientific Diagram